Side-by-side · Research reference
DSIPvsKPV
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/36 cited
BAnimal-StrongDraft13/39 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
01Mechanism of Action
Parameter
DSIP
KPV
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Feedback intact?
—
No melanocortin receptor binding
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
KPV
Frequency
Once daily, pre-sleep
Daily or 2–3× per week
Lower / starter dose
50 mcg pre-sleep
100 mcg / day
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Duration
8–12 weeks per cycle
4–8 weeks per cycle
Reconstitution
Bacteriostatic water
Bacteriostatic water (SQ form)
Timing
30–60 min pre-sleep
No specific time; often taken with / before meals (oral)
Half-life
Short plasma; CNS effects last hours
Hours (estimated; rapid tissue uptake)
04Side Effects & Safety
Parameter
DSIP
KPV
Injection site reaction
Mild irritation
Mild irritation
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
Limited human data
Pregnancy / OB
Avoid
Avoid — insufficient data
GI symptoms
—
Rare nausea (oral form)
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
KPV
- ·Pregnancy / breastfeeding
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
KPV
- ·Active autoimmune disease (theoretical)
05Administration Protocol
Parameter
DSIP
KPV
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Add 1 mL bacteriostatic water to vial per labelling.
2. Injection site
SQ — abdomen. Rotate sites.
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
3. Timing
30–60 min pre-sleep.
Morning preferred; oral form taken with / before meals.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G insulin syringe.
29–31G insulin syringe (SQ form).
06Stack Synergy
DSIP
— no documented stacks
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions